Merck -- 20yr cycle bottomPosted By Paul Kammueller |
Blood in the streets on this stock, folks. Plummeting on news of the Vioxx recall, further plummeted on expectations of a zillion class-action lawsuits, this stock has taken a very fast run to its long-term channel bottom (may or may not have reached it, depending on how close I can draw the line, but it's pretty darn close right now) -- dividend yield now at 5%, a good candidate for bottom-fishers. But if it goes down much further the chart becomes long-term 'broken' (like Microsoft and AT&T) implying that something fundamental has changed and all future bets are off.